BIOMARIN PHARMACEUTICAL INC Insider Trading for March 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BIOMARIN PHARMACEUTICAL INC for March 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 78.47 | 1,618 | 126,964 | 67,008 | 68.6 K to 67 K (-2.36 %) |
| Mar 26 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 74.36 | 2,041 | 151,769 | 68,626 | 70.7 K to 68.6 K (-2.89 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Payment of Exercise | F | 73.05 | 3,501 | 255,748 | 117,138 | 120.6 K to 117.1 K (-2.90 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 73.05 | 3,309 | 241,722 | 77,842 | 81.2 K to 77.8 K (-4.08 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 73.05 | 5,836 | 426,320 | 139,869 | 145.7 K to 139.9 K (-4.01 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 73.05 | 13,128 | 959,000 | 297,213 | 310.3 K to 297.2 K (-4.23 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 73.05 | 3,599 | 262,907 | 70,667 | 74.3 K to 70.7 K (-4.85 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Payment of Exercise | F | 73.05 | 414 | 30,243 | 24,781 | 25.2 K to 24.8 K (-1.64 %) |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 21.51 | 3,750 | 80,663 | 0 | |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 75.39 | 3,750 | 282,713 | 18,980 | 22.7 K to 19 K (-16.50 %) |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 21.51 | 3,750 | 80,663 | 22,730 | 19 K to 22.7 K (+19.76 %) |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 76.52 | 4,610 | 352,757 | 18,980 | 23.6 K to 19 K (-19.54 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Option Exercise | A | 73.82 | 9,600 | 708,672 | 9,600 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 0.00 | 6,730 | 0 | 25,195 | 18.5 K to 25.2 K (+36.45 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Payment of Exercise | F | 84.50 | 1,303 | 110,104 | 18,465 | 19.8 K to 18.5 K (-6.59 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 73.82 | 28,790 | 2,125,278 | 28,790 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 10,100 | 0 | 81,151 | 71.1 K to 81.2 K (+14.22 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 84.50 | 7,244 | 612,118 | 71,051 | 78.3 K to 71.1 K (-9.25 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 73.82 | 51,970 | 3,836,425 | 51,970 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 18,220 | 0 | 145,705 | 127.5 K to 145.7 K (+14.29 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 84.50 | 10,496 | 886,912 | 127,485 | 138 K to 127.5 K (-7.61 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Option Exercise | A | 73.82 | 30,390 | 2,243,390 | 30,390 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Grant | A | 0.00 | 10,660 | 0 | 120,639 | 110 K to 120.6 K (+9.69 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Payment of Exercise | F | 84.50 | 7,600 | 642,200 | 109,979 | 117.6 K to 110 K (-6.46 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 73.82 | 127,920 | 9,443,054 | 127,920 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 44,850 | 0 | 310,341 | 265.5 K to 310.3 K (+16.89 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 84.50 | 30,952 | 2,615,444 | 265,491 | 296.4 K to 265.5 K (-10.44 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 73.82 | 29,590 | 2,184,334 | 29,590 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 10,380 | 0 | 74,266 | 63.9 K to 74.3 K (+16.25 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 84.50 | 7,644 | 645,918 | 63,886 | 71.5 K to 63.9 K (-10.69 %) |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 10,000 | 215,100 | 79,000 | |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.52 | 10,000 | 895,200 | 296,443 | 306.4 K to 296.4 K (-3.26 %) |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 10,000 | 215,100 | 306,443 | 296.4 K to 306.4 K (+3.37 %) |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | L | 94.39 | 30 | 2,832 | 296,443 | 296.4 K to 296.4 K (+0.01 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 13,136 | 0 | 137,981 | 124.8 K to 138 K (+10.52 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 9,586 | 0 | 78,295 | 68.7 K to 78.3 K (+13.95 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 35,580 | 0 | 296,413 | 260.8 K to 296.4 K (+13.64 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Grant | A | 0.00 | 9,852 | 0 | 117,579 | 107.7 K to 117.6 K (+9.15 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,586 | 0 | 71,530 | 61.9 K to 71.5 K (+15.48 %) |